BACKGROUND: There is a paucity of data on the response of breast cancer to neoadjuvant c in low-resources developing African countries such as Nigeria. We therefore decided to study the impact of neoadjuvant chemotherapy on breast cancer patients in Nigeria in the light of constrained resources. METHODS: This was a single-center retrospective descriptive study. Sixty-two patients with locally advanced breast cancer treated with neoadjuvant chemotherapy in the last 24 years in Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria, constituted the study population. The outcome measures were clinical tumor response, disease-free survival, overall survival, and chemotherapy toxicity profile. RESULTS: Patients ranged in age from 30 to 85 years (mean = 49.1 +/- SD 12.7 years) and included one male. After three cycles of chemotherapy, complete clinical response was observed in 4 patients (6.5%), partial clinical response in 28 patients (45.2%), no clinically measurable response in 24 patients (38.7%), and progressive disease in 6 patients (9.7%). Forty-one patients completed six cycles, of which 9 patients (22.0%) had complete clinical response and 12 patients (29.3%) had partial clinical response. Four of 30 patients (13.3%) with tumor size of 6-10 cm had complete clinical response, while no patient with a tumor bigger than 10 cm had complete clinical response. Of the 62 patients, 42 were followed up for more than 1 year. The 1-, 2-, and 5-year survival rates of this cohort were 66.7, 42.9, and 11.9%, respectively The median follow-up period was 9 months and the disease-free survival and overall survival rates at median follow-up period were 45 and 37%, respectively. CONCLUSION: There was a poor overall clinical response rate to neoadjuvant chemotherapy in the Black population studied. Late presentation with large tumor mass may be accountable for this.
BACKGROUND: There is a paucity of data on the response of breast cancer to neoadjuvant c in low-resources developing African countries such as Nigeria. We therefore decided to study the impact of neoadjuvant chemotherapy on breast cancerpatients in Nigeria in the light of constrained resources. METHODS: This was a single-center retrospective descriptive study. Sixty-two patients with locally advanced breast cancer treated with neoadjuvant chemotherapy in the last 24 years in Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria, constituted the study population. The outcome measures were clinical tumor response, disease-free survival, overall survival, and chemotherapy toxicity profile. RESULTS:Patients ranged in age from 30 to 85 years (mean = 49.1 +/- SD 12.7 years) and included one male. After three cycles of chemotherapy, complete clinical response was observed in 4 patients (6.5%), partial clinical response in 28 patients (45.2%), no clinically measurable response in 24 patients (38.7%), and progressive disease in 6 patients (9.7%). Forty-one patients completed six cycles, of which 9 patients (22.0%) had complete clinical response and 12 patients (29.3%) had partial clinical response. Four of 30 patients (13.3%) with tumor size of 6-10 cm had complete clinical response, while no patient with a tumor bigger than 10 cm had complete clinical response. Of the 62 patients, 42 were followed up for more than 1 year. The 1-, 2-, and 5-year survival rates of this cohort were 66.7, 42.9, and 11.9%, respectively The median follow-up period was 9 months and the disease-free survival and overall survival rates at median follow-up period were 45 and 37%, respectively. CONCLUSION: There was a poor overall clinical response rate to neoadjuvant chemotherapy in the Black population studied. Late presentation with large tumor mass may be accountable for this.
Authors: Benjamin O Anderson; Roman Shyyan; Alexandru Eniu; Robert A Smith; Cheng-Har Yip; Nuran Senel Bese; Louis W C Chow; Shahla Masood; Scott D Ramsey; Robert W Carlson Journal: Breast J Date: 2006 Jan-Feb Impact factor: 2.431
Authors: Elima Jedy-Agba; Maria Paula Curado; Olufemi Ogunbiyi; Emmanuel Oga; Toyin Fabowale; Festus Igbinoba; Gloria Osubor; Theresa Otu; Henry Kumai; Alice Koechlin; Patience Osinubi; Patrick Dakum; William Blattner; Clement A Adebamowo Journal: Cancer Epidemiol Date: 2012-05-22 Impact factor: 2.984
Authors: Olalekan Olasehinde; Olusegun I Alatise; Olukayode A Arowolo; Victoria L Mango; Olalere S Olajide; Adeleye D Omisore; Carla Boutin-Foster; Thomas P Kingham Journal: Eur J Cancer Care (Engl) Date: 2019-01-06 Impact factor: 2.520
Authors: Paul Ruff; Herbert Cubasch; Maureen Joffe; Evan Rosenbaum; Nivashni Murugan; Ming-Chih Tsai; Oluwatosin Ayeni; Katherine D Crew; Judith S Jacobson; Alfred I Neugut Journal: Cancer Manag Res Date: 2018-02-09 Impact factor: 3.989
Authors: Olukayode A Arowolo; Uchenna O Njiaju; Temidayo O Ogundiran; Oyewale Abidoye; Olukayode O Lawal; Millicent Obajimi; Adebayo V Adetiloye; Hae K Im; Akinbolaji A Akinkuolie; Abideen Oluwasola; Kayode Adelusola; Adesunkanmi A Kayode; Augustine E Agbakwuru; Helen Oduntan; Chinedum P Babalola; Gini Fleming; Olusola C Olopade; Adeyinka Gladys Falusi; Muheez A Durosinmi; Olufunmilayo I Olopade Journal: Breast J Date: 2013-07-19 Impact factor: 2.431
Authors: Adeyinka A Adejumo; Olusola J Ajamu; Olusola O Akanbi; John C Onwukwe; Oluseyi A Adeosun; Paul O Omoregie; Aaron Amos; Yakubu Garba; Oyintobra F Koroye; Stephen E Garba Journal: Niger Med J Date: 2019-11-25